ResMed (NYSE:RMD) Given New $200.00 Price Target at Oppenheimer

ResMed (NYSE:RMD – Get Free Report) had its target price dropped by equities researchers at Oppenheimer from $205.00 to $200.00 in a research report issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Oppenheimer’s price target suggests a potential downside of 7.91% from the company’s current […]

Related Keywords

Canada ,Czech Republic ,Czech ,Peterc Farrell , ,Ae Wealth Management ,Keycorp ,Caprock Group ,Czech National Bank ,Securities Exchange Commission ,Royal Bank ,Resmed Company Profile ,Needham Company ,Jpmorgan Chase Co ,Simplicity Solutions ,Resmed Inc ,Get Free Report ,Director Peter ,Exchange Commission ,General Counsel Michael ,National Bank ,Med Inc ,Respiratory Care ,Resmed Daily ,Resmed ,Nyse Rmd ,Rmd ,Medical ,76115210 ,Lower Price Target ,Oppenheimer Holdings Inc ,